Intensified regimen for advanced head and neck squamous cell carcinomas

Arch Otolaryngol Head Neck Surg. 1997 Feb;123(2):139-44. doi: 10.1001/archotol.1997.01900020013002.

Abstract

Objective: To devise an intensified treatment regimen for patients with advanced, resectable head and neck squamous cell carcinomas.

Design: Phase I/II clinical trial consisting of perioperative cisplatin chemoradiotherapy, surgical resection, intraoperative radiotherapy, and postoperative cisplatin chemoradiotherapy.

Setting: The Ohio State University Comprehensive Cancer Center, Columbus.

Patients: Thirty-seven patients (median age, 63 years) with advanced oral cavity, oropharyngeal, or hypopharyngeal carcinomas.

Results: The range of time at risk was 1 to 30 months (median, 21 months). Thirty of the 37 registered patients were analyzable; 11 have died (5 with distant metastases; 1 of lung carcinoma; and 5 were cancer-free); 2 experienced second primary tumors in the oral cavity (out of or adjacent to the previous radiotherapy portals). Treatment compliance was excellent (92%), morbidity was low, and excellent locoregional control was achieved.

Conclusions: The initial results are encouraging; the future strategy will intensify the systemic component of therapy based on results from concurrent laboratory studies.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / secondary
  • Carcinoma, Squamous Cell / therapy*
  • Cisplatin / therapeutic use
  • Clinical Protocols
  • Combined Modality Therapy
  • Female
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance
  • Radiotherapy Dosage
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Cisplatin